The Broad Institute, Inc.

Massachusetts Institute of Technology

Beth Israel Deaconess Medical Center, Inc.

Chris Dockendorff

Benito Munoz

Sivaraman Dandapani

Partha Pratim Nag

Monty Krieger

Robert Flaumenhaft

Miao Yu

Willmen Youngsaye

Patrick Faloon

Thomas Nieland

Timothy A Lewis

Andrew Germain

Jun Pu

Tatiana Pilyugina

Lawrence MacPherson

The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI. Formula (I) 

Compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase

This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections.

Thiazole-based inhibitors of scavenger receptor BI

This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can be used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections. The compounds have the formula: wherein Rand Rare independently H, halogen, cyano, haloalkyl, haloalkyloxy or OMe; or Rand Rtogether are &#x2014;O&#x2014;CH&#x2014; or &#x2014;O&#x2014;CF&#x2014;O&#x2014;; Ris H, halogen, cyano, haloalkyl or haloalkyloxy; Ris Calkyl, Ccycloalkyl, Ccycloalkylmethyl or Ccycloheteroalkyl, wherein the heteroatom is N or O; Ris H or CH; Ris Calkyl or Ccycloalkyl; and A, B, D and E are each, independently, CH, N, O or S, wherein at least one of A, B, D and E is N, and another of A, B, D and E is N, O or S. 

Heterocycle-bisamide inhibitors of scavenger receptor BI

The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof. 

Compounds and methods for treating diseases mediated by protease activated receptors

Growing community of inventors

Arlington, MA, United States of America

Chris Dockendorff